IDH3A and central nervous system cancer: More precise subcategorization of treatment criteria has been introduced to the new edition of the WHO recommendations on glioma for patients with various prognoses and medication sensitivity, including isocitrate dehydrogenase IDH mutations, 1p/19q co-deletions, and MGMT promoter methylation16.